Anthos Therapeutics on LinkedIn: Atrial Fibrillation Study Shows Overwhelming Benefit for Abelacimab vsโ€ฆ

#NEWS: Anthos Therapeutics today announced that the AZALEA TIMI-71 atrial fibrillation study with the dual-acting Factor XI / XIa inhibitor, abelacimab, wasโ€ฆ

Read the full article here

Related Articles